About

AbHelix is an early-stage therapeutic antibody discovery company dedicated to harnessing the power of genomics to discover innovative immunotherapeutics.

 

Leveraging cutting-edge genomics platform technologies to comprehensively and cost-effectively sequence profile the human immune repertoire, we aim to identify therapeutic antibodies directly evolved within the human immune system.

 

The current AbHelix team consists of passionate researchers with deep genomics expertise and extensive business experience, guided by experienced advisors and successful entrepreneurs/investors.

 

We actively seek innovative and dedicated talents to join our efforts to realize the full potential of genomics in human immunotherapeutics discovery.